XERS
Research Snapshot
Static fundamentals, valuation context, and investor signals for XERIS BIOPHARMA HOLDINGS, INC. (XERS).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
0.2%
ROIC, 9.8% FCF margin
Growth
70.7%
5Y sales (revenue) CAGR
Balance sheet
16.1x
Debt/equity, 2.2x current ratio
Superinvestors
0
No tracked positions
Strengths to research
- Revenue compounded at 70.7% over five years.
Watchouts
- Debt/equity is high at 16.1x.
- Valuation multiples are limited or unavailable.
Annual data: 6 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for XERS.
Grade D
26
/ 100
Quality Radar0 – 20 per axis